Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) EBITDA Margin (2022 - 2025)

ARS Pharmaceuticals' EBITDA Margin history spans 4 years, with the latest figure at 146.66% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 20419.0% year-over-year to 146.66%; the TTM value through Dec 2025 reached 203.37%, down 21253.0%, while the annual FY2025 figure was 203.37%, 21253.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 146.66% at ARS Pharmaceuticals, up from 157.26% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 57.54% in Q4 2024 and bottomed at 176180.0% in Q2 2023.
  • The 4-year median for EBITDA Margin is 997.53% (2022), against an average of 21917.45%.
  • The largest annual shift saw EBITDA Margin plummeted -17479638bps in 2023 before it skyrocketed 17367260bps in 2024.
  • A 4-year view of EBITDA Margin shows it stood at 3483.07% in 2022, then crashed by -4958bps to 176180.0% in 2023, then skyrocketed by 100bps to 57.54% in 2024, then plummeted by -355bps to 146.66% in 2025.
  • Per Business Quant, the three most recent readings for SPRY's EBITDA Margin are 146.66% (Q4 2025), 157.26% (Q3 2025), and 286.32% (Q2 2025).